Aridis to Start Phase 1/2a Trial for Inhalable Antibacterial Therapy AR-501 in CF Patients

Aridis to Start Phase 1/2a Trial for Inhalable Antibacterial Therapy AR-501 in CF Patients
This post was originally published on this site

Aridis Pharmaceuticals is planning to launch a Phase 1/2a clinical trial in the beginning of 2019 to evaluate the potential of its investigational antibacterial compound AR-501 (gallium citrate) in patients with cystic fibrosis (CF).

This follows the approval of the Investigational New Drug application for AR-501 by the U.S. Food and Drug Administration (FDA).

The FDA has also granted Fast Track Designation and Qualified Infectious Disease Product Designation (QIDP) to AR-501. These are expected to support and expedite the therapy’s development and regulatory review.

“The Fast Track and QIDP product designations provide us the means to accelerate clinical development of AR-501 and could enable us to bring this innovative drug candidate to the CF patient population more quickly,” Vu Truong, PhD, CEO of Aridis Pharmaceuticals, said in a press release.

AR-501 is an inhaled form of gallium being developed to treat pulmonary bacterial infections. It works by starving bacteria of iron and inhibiting the iron-dependent metabolic processes necessary for the infection to progress, a mechanism very different from that of common antibiotics.

According to the company, AR-501 has been shown to have broad antibacterial activity with unique benefits compared to current standard-of-care antibiotics, working against antibiotic-resistant strains such as Pseudomonas aeruginosa and B. cepacia.

Results from a previous Phase 2 clinical trial (NCT02354859) demonstrated the safety and efficacy of intravenous gallium to improve lung function in CF patients.

“AR-501 has the potential to offer patients more convenient dosing (once per week) versus standard- of-care inhaled antibiotics (several times per day),” and with a “more effective delivery route than (IV) administered gallium,” Truong said.

In addition, it is a broad-spectrum antimicrobial agent “with a low propensity for developing drug resistance,” he said.

The new Phase 1/2a trial will be conducted with the support of the Cystic Fibrosis Foundation (CFF).

The CFF has increased the value of the grant previously agreed to with Aridis to up to $7.5 million, contingent on the achievement of AR-501 development milestones, the company announced.

“The additional funding will expedite clinical development and demonstrates the CF Foundation’s continued support for the clinical development of AR-501,” Truong said.

The post Aridis to Start Phase 1/2a Trial for Inhalable Antibacterial Therapy AR-501 in CF Patients appeared first on Cystic Fibrosis News Today.

Chris Comish serves as the Publisher of the website, and is responsible for directing the editorial focus as well as putting the finishing touches on many featured articles.